What further data are needed to value the Multi‐Biomarker Disease Activity score for measuring <scp>rheumatoid arthritis</scp> disease activity: comment on the article by Johnson et al

Masi, Alfonse T.

doi:10.1002/acr.24248

Search citation statements

Order By: Relevance

Paper Sections

Select...

Protein Biomarkers1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Book1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MBDA scores at baseline have been associated with patients' response to anti-TNF therapy (Table 2). On the other hand, a randomized prospective study did not find a correlation between MBDA score and different clinical scores in patients treated with adalimumab or abatacept [125], and the contribution of the MBDA score to personalized patient management is still under discussion [174][175][176].…”

Section: Protein Biomarkersmentioning

confidence: 99%

Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers

Mezghiche

Yahia-Cherbal

Rogge

et al. 2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

transcriptional, protein, cellular) may be necessary to capture the biological complexity of response to treatment.• New bioinformatic tools, including machine learning approaches, are necessary to handle the complexity of the large data sets being currently explored. * This paper explores the ability of random forest-based algorithms to model gene expression and DNA methylation data in order to predict therapeutic responses in RA.

show abstract